Work

Development of an all-in-one pan-sarbecovirus ferritin nanoparticle vaccine in humans

Year: 2024

Type: article

Abstract: A recent human clinical trial published in The Lancet Microbe by Brittany L Ober Shepher and colleagues1 showed that a spike ferritin nanoparticle (SpFN) vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21 (SpFN-ALFQ) was well tolerated and safe. The vaccine elicited broadly protective immunity against several evolving SARS-CoV-2 variants and subvariants and even a panel of sarbecoviruses.1 The study findings further advance the development of next-generation pan-sarbecovirus vaccines.

Source: The Lancet Microbe

DOI: 10.1016/j.lanmic.2024.100974

Authors: Liuying Li, Hao Zhou

Institutions: Zigong First People's Hospital, Chengdu University of Traditional Chinese Medicine

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $6,300